🟢 Moleculin Biotech is trading 10.25% up today ahead of AACR Annamycin pancreatic-cancer data

Moleculin Biotech is trading 10.25% higher at $0.62 as investors anticipate new Annamycin pancreatic-cancer data at AACR.

• The abstract is scheduled for publication at 1:00 p.m. ET on September 25, 2026, ahead of presentations running September 25–28.
• The study examines Annamycin’s antitumor activity and CD8+ T-cell involvement in pancreatic tumors.